New England Nuclear (LNTH) & The Competition Financial Comparison

New England Nuclear (NASDAQ: LNTH) is one of 25 public companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare New England Nuclear to similar businesses based on the strength of its valuation, dividends, analyst recommendations, profitability, earnings, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for New England Nuclear and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
New England Nuclear 0 1 3 0 2.75
New England Nuclear Competitors 102 376 574 19 2.48

New England Nuclear presently has a consensus price target of $24.00, suggesting a potential upside of 38.33%. As a group, “Diagnostic substances” companies have a potential upside of 8.66%. Given New England Nuclear’s stronger consensus rating and higher probable upside, research analysts clearly believe New England Nuclear is more favorable than its competitors.

Insider and Institutional Ownership

89.9% of New England Nuclear shares are held by institutional investors. Comparatively, 52.1% of shares of all “Diagnostic substances” companies are held by institutional investors. 1.2% of New England Nuclear shares are held by insiders. Comparatively, 12.7% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

New England Nuclear has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, New England Nuclear’s competitors have a beta of 1.44, suggesting that their average stock price is 44% more volatile than the S&P 500.

Profitability

This table compares New England Nuclear and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
New England Nuclear 37.23% -68.13% 14.00%
New England Nuclear Competitors -583.73% -65.87% -25.47%

Earnings & Valuation

This table compares New England Nuclear and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
New England Nuclear $331.38 million $123.38 million 17.35
New England Nuclear Competitors $308.36 million $13.11 million -43.25

New England Nuclear has higher revenue and earnings than its competitors. New England Nuclear is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

New England Nuclear beats its competitors on 10 of the 13 factors compared.

New England Nuclear Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Receive News & Ratings for New England Nuclear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New England Nuclear and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Hosking Partners LLP Buys 11,408 Shares of Garmin Ltd.
Hosking Partners LLP Buys 11,408 Shares of Garmin Ltd.
3,531 Shares in Anadarko Petroleum Co.  Acquired by Fayez Sarofim & Co
3,531 Shares in Anadarko Petroleum Co. Acquired by Fayez Sarofim & Co
Nike  Shares Sold by Fayez Sarofim & Co
Nike Shares Sold by Fayez Sarofim & Co
Magellan Midstream Partners, L.P.  Stake Increased by Fayez Sarofim & Co
Magellan Midstream Partners, L.P. Stake Increased by Fayez Sarofim & Co
Brokerages Expect MB Financial Inc  to Announce $0.68 Earnings Per Share
Brokerages Expect MB Financial Inc to Announce $0.68 Earnings Per Share
Frequency Electronics  Earns Media Impact Rating of 0.15
Frequency Electronics Earns Media Impact Rating of 0.15


© 2006-2018 Ticker Report. Google+.